UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Impact of mild thrombocytopenia on bleeding and recurrent thrombosis in cancer

Haematologica (Roma), 2024-06

2024

Volltextzugriff (PDF)

Postthrombotic syndrome and quality of life after deep vein thrombosis in patients treated with edoxaban versus warfarin

Research and practice in thrombosis and haemostasis, 2022-07, Vol.6 (5), p.e12748-n/a, Article e12748

2022

Volltextzugriff (PDF)

Quality of life in patients with pulmonary embolism treated with edoxaban versus warfarin

Research and practice in thrombosis and haemostasis, 2021-07, Vol.5 (5), p.e12566-n/a, Article e12566

2021

Volltextzugriff (PDF)

Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial

European heart journal, 2019-05, Vol.40 (19), p.1541-1550

2019

Volltextzugriff (PDF)

Impact of Thrombocytopenia on Bleeding and Recurrent Thrombosis in Cancer Associated Thrombosis: A Post Hoc Analysis of Hokusai VTE Cancer Study

Blood, 2022-11, Vol.140 (Supplement 1), p.5675-5676

2022

Volltextzugriff (PDF)

Edoxaban Versus Warfarin Stratified by Average Blood Pressure in 19 679 Patients With Atrial Fibrillation and a History of Hypertension in the ENGAGE AF-TIMI 48 Trial

Hypertension (Dallas, Tex. 1979), 2019-09, Vol.74 (3), p.597-605

2019

Volltextzugriff (PDF)

Recurrent venous thromboembolism during anticoagulation with edoxaban or warfarin: A post hoc analysis of the Hokusai-VTE trial

Thrombosis research, 2020-11, Vol.195, p.209-214

2020

Volltextzugriff (PDF)

Pharmacokinetics of the Direct Factor Xa Inhibitor Edoxaban and Digoxin Administered Alone and in Combination

Journal of cardiovascular pharmacology, 2012-10, Vol.60 (4), p.335-341

2012

Volltextzugriff (PDF)

Inhibition of thrombin-activatable fibrinolysis inhibitor via DS-1040 to accelerate clot lysis in patients with acute pulmonary embolism: a randomized phase 1b study

Journal of thrombosis and haemostasis, 2023-10, Vol.21 (10), p.2929-2940

2023

Volltextzugriff (PDF)

Long‐term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and meta‐analysis

Journal of thrombosis and haemostasis, 2021-11, Vol.19 (11), p.2801-2813

2021

Volltextzugriff (PDF)

TCT-397 Edoxaban versus Standard of Care and their Effects on Clinical Outcomes in Patients having undergone Transcatheter Aortic Valve Implantation in Atrial Fibrillation – Rationale and Design of the ENVISAGE-TAVI AF Trial

Journal of the American College of Cardiology, 2017-10, Vol.70 (18), p.B163-B163

2017

Volltextzugriff (PDF)

THE IMPACT OF PROTHROMBIN COMPLEX CONCENTRATE ON THE ANTICOAGULATORY EFFECTS OF EDOXABAN

Journal of the American College of Cardiology, 2014-04, Vol.63 (12), p.A2095-A2095

2014

Volltextzugriff (PDF)

A Randomized, Open-Label, Blinded Outcome Assessment Trial Evaluating the Efficacy and Safety of LMWH/Edoxaban Versus Dalteparin for Venous Thromboembolism Associated with Cancer: Hokusai VTE-Cancer Study

Blood, 2017-12, Vol.130 (Suppl_1), p.LBA-6-LBA-6

2017

Volltextzugriff (PDF)

Abstract 19119: Concomitant Use of Antiplatelet Therapy with Edoxaban or Warfarin in Patients with Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial

Circulation (New York, N.Y.), 2014-11, Vol.130 (suppl_2)

2014

Volltextzugriff (PDF)

Abstract 12680: Efficacy and Safety of Edoxaban Compared With Warfarin in Patients With Atrial Fibrillation and Heart Failure: Insights From Engage-AF TIMI 48

Circulation (New York, N.Y.), 2014-11, Vol.130 (suppl_2)

2014

Volltextzugriff (PDF)

RELATIONSHIP BETWEEN DOSE, ANTI-FACTOR XA ACTIVITY, AND OUTCOMES IN PATIENTS RANDOMIZED TO EDOXABAN IN THE ENGAGE AF-TIMI 48 TRIAL

Journal of the American College of Cardiology, 2014-04, Vol.63 (12), p.A329-A329

2014

Volltextzugriff (PDF)

DRUG-DRUG INTERACTION STUDIES OF CARDIOVASCULAR DRUGS (AMIODARONE, DIGOXIN, QUINIDINE, ATORVASTATIN AND VERAPAMIL) INVOLVING P-GLYCOPROTEIN (P-GP), AN EFFLUX TRANSPORTER, ON THE PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF EDOXABAN, AN ORAL FACTOR XA INHIBITOR

Journal of the American College of Cardiology, 2011-04, Vol.57 (14), p.E1510-E1510

2011

Volltextzugriff (PDF)

Cerebrovascular Events in 21105 Patients With Atrial Fibrillation Randomized to Edoxaban Versus Warfarin Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48

Stroke (1970), 2014, Vol.45 (8), p.2372-2378

2014

Volltextzugriff (PDF)

CARDIAC STRUCTURE AND FUNCTION AND CHADS2 RISK SCORE IN PATIENTS WITH ATRIAL FIBRILLATION: THE EFFECTS ANTICOAGULATION WITH FACTOR XA NEXT GENERATION IN AFTHROMBOLYSIS IN MYOCARDIAL INFARCTION 48 (ENGAGE AF -TIMI 48) ECHOCARDIOGRAPHIC STUDY

Journal of the American College of Cardiology, 2013-03, Vol.61 (10), p.E964-E964

2013

Volltextzugriff (PDF)

Edoxaban versus Warfarin in Patients with Atrial Fibrillation

The New England journal of medicine, 2013, Vol.369 (22), p.2093-2104

2013

Volltextzugriff (PDF)

An Analysis of Paediatric CD4 Counts for Acquired Immune Deficiency Syndrome Using Flexible Random Curves

Applied Statistics, 1996-01, Vol.45 (2), p.151-163

1996

Volltextzugriff (PDF)

Multivariate analysis of variance and robust estimation of covariance structures when the data are curves

Shi, Minggao

1993

Volltextzugriff (PDF)

Early levels of CD4, neopterin, and β2-Microglobulin indicate future disease progression

Journal of clinical immunology, 1997, Vol.17 (1), p.43-52

1997

Volltextzugriff (PDF)

Early Levels of CD4, Neopterin, and [beta]^sub 2^-Microglobulin Indicate Future Disease Progression

Journal of clinical immunology, 1997-01, Vol.17 (1), p.43

1997

Volltextzugriff (PDF)

Replacing Time Since Human Immunodeficiency Virus Infection by Marker Values in Predicting Residual Time to Acquired Immunodeficiency Syndrome Diagnosis

Journal of acquired immune deficiency syndromes and human retrovirology, 1996-07, Vol.12 (3), p.309-316

1996

Volltextzugriff (PDF)

1 – 25 von 51

Suche als RSS-Feed

Aktive Filter

KollektionMEDLINE

KollektionThieme - Connect here FIRST to enable access

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(43)
Mit Volltextzugriff
(45)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(30)
Technology
(17)
Life Sciences & Biomedicine
(13)
Engineering
(10)
Energy & Fuels
(8)
Cardiovascular System & Cardiology
(7)
Engineering, Electrical & Electronic
(7)
Hematology
(6)
Materials Science
(6)
Materials Science, Multidisciplinary
(6)
Peripheral Vascular Disease
(6)
Physical Sciences
(6)
Biological And Medical Sciences
(5)
Edoxaban
(5)
Medical Sciences
(5)
Thermal Runaway
(5)
Batteries
(4)
Cardiovascular
(4)
Energy
(4)
Internal Medicine
(4)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Impact of mild thrombocytopenia on bleeding and recurrent thrombosis in cancer

Postthrombotic syndrome and quality of life after deep vein thrombosis in patients treated with edoxaban versus warfarin

Quality of life in patients with pulmonary embolism treated with edoxaban versus warfarin

Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial

Impact of Thrombocytopenia on Bleeding and Recurrent Thrombosis in Cancer Associated Thrombosis: A Post Hoc Analysis of Hokusai VTE Cancer Study

Edoxaban Versus Warfarin Stratified by Average Blood Pressure in 19 679 Patients With Atrial Fibrillation and a History of Hypertension in the ENGAGE AF-TIMI 48 Trial

Recurrent venous thromboembolism during anticoagulation with edoxaban or warfarin: A post hoc analysis of the Hokusai-VTE trial

Pharmacokinetics of the Direct Factor Xa Inhibitor Edoxaban and Digoxin Administered Alone and in Combination

Inhibition of thrombin-activatable fibrinolysis inhibitor via DS-1040 to accelerate clot lysis in patients with acute pulmonary embolism: a randomized phase 1b study

Long‐term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and meta‐analysis

TCT-397 Edoxaban versus Standard of Care and their Effects on Clinical Outcomes in Patients having undergone Transcatheter Aortic Valve Implantation in Atrial Fibrillation – Rationale and Design of the ENVISAGE-TAVI AF Trial

THE IMPACT OF PROTHROMBIN COMPLEX CONCENTRATE ON THE ANTICOAGULATORY EFFECTS OF EDOXABAN

A Randomized, Open-Label, Blinded Outcome Assessment Trial Evaluating the Efficacy and Safety of LMWH/Edoxaban Versus Dalteparin for Venous Thromboembolism Associated with Cancer: Hokusai VTE-Cancer Study

Abstract 19119: Concomitant Use of Antiplatelet Therapy with Edoxaban or Warfarin in Patients with Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial

Abstract 12680: Efficacy and Safety of Edoxaban Compared With Warfarin in Patients With Atrial Fibrillation and Heart Failure: Insights From Engage-AF TIMI 48

RELATIONSHIP BETWEEN DOSE, ANTI-FACTOR XA ACTIVITY, AND OUTCOMES IN PATIENTS RANDOMIZED TO EDOXABAN IN THE ENGAGE AF-TIMI 48 TRIAL

DRUG-DRUG INTERACTION STUDIES OF CARDIOVASCULAR DRUGS (AMIODARONE, DIGOXIN, QUINIDINE, ATORVASTATIN AND VERAPAMIL) INVOLVING P-GLYCOPROTEIN (P-GP), AN EFFLUX TRANSPORTER, ON THE PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF EDOXABAN, AN ORAL FACTOR XA INHIBITOR

Cerebrovascular Events in 21105 Patients With Atrial Fibrillation Randomized to Edoxaban Versus Warfarin Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48

CARDIAC STRUCTURE AND FUNCTION AND CHADS2 RISK SCORE IN PATIENTS WITH ATRIAL FIBRILLATION: THE EFFECTS ANTICOAGULATION WITH FACTOR XA NEXT GENERATION IN AFTHROMBOLYSIS IN MYOCARDIAL INFARCTION 48 (ENGAGE AF -TIMI 48) ECHOCARDIOGRAPHIC STUDY

Edoxaban versus Warfarin in Patients with Atrial Fibrillation

An Analysis of Paediatric CD4 Counts for Acquired Immune Deficiency Syndrome Using Flexible Random Curves

Multivariate analysis of variance and robust estimation of covariance structures when the data are curves

Early levels of CD4, neopterin, and β2-Microglobulin indicate future disease progression

Early Levels of CD4, Neopterin, and [beta]^sub 2^-Microglobulin Indicate Future Disease Progression

Replacing Time Since Human Immunodeficiency Virus Infection by Marker Values in Predicting Residual Time to Acquired Immunodeficiency Syndrome Diagnosis

Aktive Filter

Suchergebnisse filtern